/

Empresas

Ar

No verificado

Ariceum Therapeutics

Sobre qué escribimos

BiologíaBiotecnologíaEconomíaFarmacéuticaSanidad

11 Comunicados de prensa

Ver todos los comunicados de prensa

10/11/2025

Biotecnología

Medicina Salud Bienestar

Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma

Fuente

Ariceum Therapeutics

Editor

1.00

0

08/10/2025

Biotecnología

Anuncios breves

Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma

Fuente

Ariceum Therapeutics

Editor

1.00

0

25/08/2025

Biotecnología

Medicina Salud Bienestar

Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development

Fuente

Ariceum Therapeutics

Editor

1.00

0

06/02/2025

Farmacéutica

Sanidad

Biología

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics' Proprietary Radiopharmaceutical Cancer Therapy

Fuente

Ariceum Therapeutics

Editor

1.00

0

14/01/2025

Farmacéutica

Sanidad

Biología

FDA Clears Ariceum Therapeutics' 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

Fuente

Ariceum Therapeutics

Editor

1.00

0

10/01/2025

Farmacéutica

Sanidad

Economía

Gestión empresarial

Administración de Empresas

Biología

David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics

Fuente

Ariceum Therapeutics

Editor

1.00

0

11/12/2024

Farmacéutica

Sanidad

Empresas

Administración de Empresas

Biología

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225

Fuente

Ariceum Therapeutics

Editor

1.00

0

05/12/2024

Farmacéutica

Sanidad

Biología

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

Fuente

Ariceum Therapeutics

Editor

1.00

0

22/10/2024

Farmacéutica

Sanidad

Ciencia

Biología

Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024

Fuente

Ariceum Therapeutics

Editor

1.00

0

25/07/2024

Farmacéutica

Sanidad

Economía

Start-up

Biología

Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma

Fuente

Ariceum Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0